GlassScriptPhysician profile
Robin Andrew Walker
NPI 1891917209
$4,408.57
in general payments reported to CMS, 2019-2025
32 companies · $1,297 in 2025
The $1,297 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $402 · 2021: $435 · 2022: $727 · 2023: $565 · 2024: $725 · 2025: $1,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,586.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,135.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $598.47 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $389.31 | 2019-2025 | |
| Lilly USA, LLC | $341.07 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $291.09 | 2022-2025 | |
| Abbvie INC. | $246.42 | 2020-2025 | Ubrelvy, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $230.58 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $160.06 | 2019-2022 | |
| Astellas Pharma US INC | $126.05 | 2020-2025 | Veozah |
| Merck Sharp & Dohme LLC | $108.12 | 2021-2024 | Vaxelis, Gardasil, Capvaxive |
| Janssen Pharmaceuticals, INC | $91.51 | 2020-2022 | |
| Glaxosmithkline, LLC. | $80.81 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $70.70 | 2022-2025 | Eliquis |
| Medtronic, INC. | $67.48 | 2025 | Intellis Adaptivestim |
| Takeda Pharmaceuticals U.S.A., INC. | $53.53 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $48.83 | 2024-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $37.61 | 2024-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.48 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $30.11 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amarin Pharma, INC. | $29.93 | 2020 | |
| Esperion Therapeutics, INC. | $25.74 | 2021 | |
| Tris Pharma INC | $25.72 | 2019 | |
| Allergan, INC. | $24.70 | 2020 | |
| Abbott Laboratories | $24.34 | 2025 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $21.70 | 2024 | Inspire |
| Seqirus USA INC | $20.44 | 2025 | Flucelvax, Fluad |
| Alexion Pharmaceuticals, INC. | $18.70 | 2020 | |
| Eisai INC. | $16.82 | 2020 | |
| Tolmar, INC. | $15.85 | 2024 | |
| Cranial Technologies, INC | $15.28 | 2025 | Doc Band |
| Corium, LLC | $13.61 | 2023 | Adlarity |
| Phathom Pharmaceuticals, INC. | $13.10 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.